June 2022 DAIT Council-Approved Concepts

Concepts represent early planning stages for program announcements, requests for applications, notices of special interest, or solicitations for Council's input. If NIAID publishes an initiative from one of these concepts, we link to it below. To find initiatives, go to Opportunities & Announcements.


Note: Council approval does not guarantee that a concept will become an initiative.

Table of Contents

Fiscal Year (FY) 2024 Division of Allergy, Immunology, and Transplantation (DAIT) Concepts

Cooperative Centers on Human Immunology

For the published request for applications, check the November 15, 2022 Guide announcement, Cooperative Centers on Human Immunology (U19, Clinical Trial Optional).

Immunity in Older Adults

Request for Applications—proposed FY 2024 initiative

Contact:
Mercy PrabhuDas
mprabhudas@mail.nih.gov

Objective: The objective of the program is to expand understanding of the changes that occur in immune function during the aging process that contribute to impaired responses to pathogens and vaccines.

Description: This initiative will continue to support human studies focused on innate and adaptive immunity, with regard to age-associated alterations in the development and function of immune responses to infectious pathogens or vaccines. In addition, a deeper understanding of the intersection between immune function during aging and susceptibility to systemic inflammatory diseases including mechanisms related to diminished resolution of inflammation is needed. Examining how aging alters communication between other cell types (e.g., platelets, adipose tissue, stromal cells), the microbiome, and immune cells to influence host responses is anticipated. This program will support an expanded effort in innate immunity; microbiome, immune-metabolic regulatory mechanisms, and mucosal immune function; tissue resident immune cells regulation of tissue function; and effects of aging on the structure and function of lymph node stroma and the functional consequences for protective immunity. The use of biospecimens from established human cohorts from independently funded clinical trials or establishment of new cohorts to study immune function will be encouraged.

Maintaining Immunity After Vaccination and Infection

For the published request for applications, check the August 22, 2022 Guide announcement, Maintaining Immunity After Immunization (U01, Clinical Trial Not Allowed).

Autoimmunity Centers of Excellence, Basic Component/Autoimmunity Centers of Excellence, Clinical Component

For the published requests for applications, check the December 22, 2022 Guide announcement, Autoimmunity Centers of Excellence, Basic Research Program (U19 Clinical Trial Not Allowed) and the December 21, 2022 Guide announcement Autoimmunity Centers of Excellence, Clinical Research Program (UM1 Clinical Trial Required).

Content last reviewed on